Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy
- PMID: 24094656
- DOI: 10.1016/j.urology.2013.04.082
Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy
Abstract
Objective: To evaluate, in detail, the histopathologic features of metastatic testicular germ cell tumors to retroperitoneal lymph nodes treated with primary retroperitoneal lymph node dissection (RPLND) and correlate the findings with patients' outcomes.
Materials and methods: We studied 183 patients with documented pathologic stage II disease with or without elevated serum tumor markers, selected from 453 patients who underwent primary RPLND at our institution from 1989 to 2002. Tumor type(s), size and extent of disease, and amount of tumor necrosis were assessed and correlated with outcome.
Results: Embryonal carcinoma was the most common tumor type, present as the only component in 99 cases (54%) and the predominant tumor type (>50%) in 142 (78%). The number of positive lymph nodes ranged from 1 to 40 from a total of 2-80 lymph nodes examined (median, 28). Extranodal extension (ENE) was identified in 120 cases (66%). Among 73 patients followed up expectantly and with normal serum tumor markers, 19 experienced relapse, the probability of which was higher in patients with more positive nodes, larger metastases, and presence of ENE. However, none of these differences was statistically significant (all P >.2). The predominance of embryonal carcinoma and the presence of tumor necrosis were not significantly associated with outcome.
Conclusion: In this cohort, most patients treated with primary RPLND and with positive lymph nodes also had ENE. We did not identify any variables to be significantly associated with relapse after RPLND in patients managed expectantly. Additional studies with more patients are needed to validate our findings.
Copyright © 2013 Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.Urology. 2013 Dec;82(6):1346. doi: 10.1016/j.urology.2013.04.083. Epub 2013 Oct 2. Urology. 2013. PMID: 24094653 No abstract available.
-
Reply: To PMID 24094653.Urology. 2013 Dec;82(6):1346-7. doi: 10.1016/j.urology.2013.04.084. Epub 2013 Oct 2. Urology. 2013. PMID: 24094654 No abstract available.
-
[Testicular tumors - results of primary retroperitoneal lymphadenectomy].Aktuelle Urol. 2014 May;45(3):169-70. doi: 10.1055/s-0034-1383476. Epub 2014 Jun 16. Aktuelle Urol. 2014. PMID: 24932549 German. No abstract available.
-
Re: Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.J Urol. 2014 Aug;192(2):424. doi: 10.1016/j.juro.2014.05.017. Epub 2014 May 10. J Urol. 2014. PMID: 25034995 No abstract available.
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
